SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

4DMT Reports Third Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

EMERYVILLE, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with the potential to transform treatment paradigms and provide unprecedented benefits…

FDMT

Related stories